Friday, April 07, 2006 11:36:37 AM
Forbes.com, Peter Kang, 04.07.06, 10:11 AM ET
Morgan Stanley raised the price target on Amylin Pharmaceuticals to $52 from $42, citing strong sales for diabetes drug Byetta.
The analyst lifted the forecasted first-quarter and 2006 U.S. sales of Byetta to $75 million and $383 million, respectively, from $65 million and $348 million, citing current prescription trends and a recent price increase.
"We believe the stock could reach the low $50s with solid data at the American Diabetes Association meeting in June and continued growth trends," the analyst wrote in a Thursday note. "Performance in the second half of 2006 may be more muted as the stock trades on sentiment surrounding the DPP-IV inhibitors."
Harr maintained an "overweight" rating on the stock.
"Long-term, we continue to believe that Amylin could reach $80 to $100 over the next three to five years if Byetta LAR potential approaches our mega-blockbuster beliefs," he said.
Byetta is co-marketed by Eli Lilly. The companies, along with Alkermes, are developing a long-acting version of Byetta.
Elsewhere in the sector, Harr has "overweight" ratings on ImClone Systems, Regeneron Pharmaceuticals, Threshold Pharmaceuticals and ZymoGenetics, among others.
http://www.forbes.com/markets/economy/2006/04/07/amyln-byetta-0407markets03.html
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM